{"pmid": "11156811", "sentences": {"sent_1": {"Section": "METHODS", "text": "Sertraline treatment of generalized social phobia : a 20-week , double-blind , placebo-controlled study .", "entities": {"entity_1": {"text": "Sertraline", "class": "Intervention", "negation": 0, "UMLS": "", "start": 0}, "entity_2": {"text": "generalized social phobia", "class": "Participant", "negation": 0, "UMLS": "", "start": 3}}, "relations": {}}, "sent_2": {"Section": "METHODS", "text": "OBJECTIVE The authors evaluated the efficacy , safety , and tolerability of sertraline , a selective serotonin reuptake inhibitor , in the treatment of generalized social phobia .", "entities": {"entity_3": {"text": "efficacy", "class": "Outcome", "negation": 0, "UMLS": "", "start": 5}, "entity_4": {"text": "safety", "class": "Outcome", "negation": 0, "UMLS": "", "start": 7}, "entity_5": {"text": "tolerability", "class": "Outcome", "negation": 0, "UMLS": "", "start": 10}, "entity_6": {"text": "sertraline", "class": "Intervention", "negation": 0, "UMLS": "", "start": 12}, "entity_7": {"text": "generalized social phobia", "class": "Participant", "negation": 0, "UMLS": "", "start": 24}}, "relations": {}}, "sent_3": {"Section": "METHODS", "text": "METHOD Adult outpatients with generalized social phobia ( N=204 ) from 10 Canadian centers were randomly assigned to receive sertraline or placebo in a 2:1 ratio for a 20-week double-blind", "entities": {"entity_8": {"text": "outpatients", "class": "Participant", "negation": 0, "UMLS": "", "start": 2}, "entity_9": {"text": "generalized social phobia", "class": "Participant", "negation": 0, "UMLS": "", "start": 4}, "entity_10": {"text": "placebo", "class": "Intervention", "negation": 0, "UMLS": "", "start": 21}, "entity_11": {"text": "a", "class": "Intervention", "negation": 0, "UMLS": "", "start": 23}}, "relations": {}}, "sent_4": {"Section": "METHODS", "text": "study following a 1-week , single-blind , placebo run-in .", "entities": {}, "relations": {}}, "sent_5": {"Section": "METHODS", "text": "The initial dose of sertraline was 50 mg/day with increases of 50 mg/day every 3 weeks permitted after the fourth week of treatment ( dosing was flexible up to a", "entities": {"entity_12": {"text": "sertraline", "class": "Intervention", "negation": 0, "UMLS": "", "start": 4}}, "relations": {}}, "sent_6": {"Section": "METHODS", "text": "maximum of 200 mg/day ) .", "entities": {}, "relations": {}}, "sent_7": {"Section": "METHODS", "text": "Primary efficacy assessments were the percentage of patients rated much or very much improved on the Clinical Global Impression ( CGI ) improvement item and the mean changes from baseline", "entities": {"entity_13": {"text": "efficacy", "class": "Outcome", "negation": 0, "UMLS": "", "start": 1}, "entity_14": {"text": "percentage of patients rated much or very much improved on the Clinical Global Impression ( CGI ) improvement item", "class": "Outcome", "negation": 0, "UMLS": "", "start": 5}, "entity_15": {"text": "mean changes from baseline", "class": "Outcome", "negation": 0, "UMLS": "", "start": 26}}, "relations": {}}, "sent_8": {"Section": "METHODS", "text": "to study endpoint in total score on the social phobia subscale of the Marks Fear Questionnaire and total score on the Brief Social Phobia Scale .", "entities": {"entity_16": {"text": "endpoint in total score on the social phobia subscale of the Marks Fear Questionnaire", "class": "Outcome", "negation": 0, "UMLS": "", "start": 2}, "entity_17": {"text": "total score on the Brief Social Phobia Scale", "class": "Outcome", "negation": 0, "UMLS": "", "start": 17}}, "relations": {}}, "sent_9": {"Section": "METHODS", "text": "RESULTS In intent-to-treat endpoint analyses of 203 of the patients , significantly more of the 134 patients given sertraline ( N=71 [ 53 % ] ) than of the 69", "entities": {"attribute_1": {"text": "more", "class": "modifier", "negation": 0, "UMLS": "", "start": 12}, "entity_18": {"text": "sertraline", "class": "Intervention", "negation": 0, "UMLS": "", "start": 18}}, "relations": {}}, "sent_10": {"Section": "METHODS", "text": "patients receiving placebo ( N=20 [ 29 % ] ) were considered responders according to their CGI improvement scores at the end of treatment .", "entities": {"entity_19": {"text": "CGI improvement scores", "class": "Outcome", "negation": 0, "UMLS": "", "start": 16}}, "relations": {}}, "sent_11": {"Section": "METHODS", "text": "The mean reductions in the social phobia subscale of the Marks Fear Questionnaire and in the total score on the Brief Social Phobia Scale were 32.6 % and 34.3 %", "entities": {"entity_20": {"text": "mean reductions in the social phobia subscale of the Marks Fear Questionnaire", "class": "Outcome", "negation": 0, "UMLS": "", "start": 1}, "entity_21": {"text": "total score on the Brief Social Phobia Scale", "class": "Outcome", "negation": 0, "UMLS": "", "start": 16}, "attribute_2": {"text": "32.6 %", "class": "measure", "negation": 0, "UMLS": "", "start": 25}, "attribute_3": {"text": "34.3 %", "class": "measure", "negation": 0, "UMLS": "", "start": 28}}, "relations": {}}, "sent_12": {"Section": "METHODS", "text": "in the sertraline group and 10.8 % and 18.6 % in the placebo group , respectively .", "entities": {"entity_22": {"text": "sertraline", "class": "Intervention", "negation": 0, "UMLS": "", "start": 2}, "attribute_4": {"text": "10.8 %", "class": "measure", "negation": 0, "UMLS": "", "start": 5}, "attribute_5": {"text": "18.6 %", "class": "measure", "negation": 0, "UMLS": "", "start": 8}, "entity_23": {"text": "placebo", "class": "Intervention", "negation": 0, "UMLS": "", "start": 12}}, "relations": {}}, "sent_13": {"Section": "METHODS", "text": "Analysis of covariance showed superiority of sertraline over placebo on all primary and secondary efficacy measures .", "entities": {"attribute_6": {"text": "superiority", "class": "modifier", "negation": 0, "UMLS": "", "start": 4}, "entity_24": {"text": "sertraline", "class": "Intervention", "negation": 0, "UMLS": "", "start": 6}, "entity_25": {"text": "placebo", "class": "Intervention", "negation": 0, "UMLS": "", "start": 8}, "entity_26": {"text": "primary and secondary efficacy measures", "class": "Outcome", "negation": 0, "UMLS": "", "start": 11}}, "relations": {}}, "sent_14": {"Section": "METHODS", "text": "Sertraline was well tolerated : 103 ( 76 % ) of the 135 sertraline-treated patients and 54 ( 78 % ) of the 69 placebo-treated patients completed the study .", "entities": {"entity_27": {"text": "Sertraline", "class": "Intervention", "negation": 0, "UMLS": "", "start": 0}, "attribute_7": {"text": "103 ( 76 % )", "class": "measure", "negation": 0, "UMLS": "", "start": 5}, "entity_28": {"text": "sertraline-treated", "class": "Intervention", "negation": 0, "UMLS": "", "start": 13}, "attribute_8": {"text": "54 ( 78 % )", "class": "measure", "negation": 0, "UMLS": "", "start": 16}}, "relations": {}}, "sent_15": {"Section": "METHODS", "text": "CONCLUSIONS Sertraline is an effective treatment for patients with generalized social phobia .", "entities": {"entity_29": {"text": "Sertraline", "class": "Intervention", "negation": 0, "UMLS": "", "start": 1}, "attribute_9": {"text": "effective", "class": "modifier", "negation": 0, "UMLS": "", "start": 4}, "entity_30": {"text": "generalized social phobia", "class": "Participant", "negation": 0, "UMLS": "", "start": 9}}, "relations": {}}}}